Cosmo Pharmaceuticals attracted welcome attention from investors and other market watchers after coming out with topline ...

Researchers say in future it may be possible to grow personalized organoids from patient’s own tissue, to test potential treatments in advance.

The market offers strong growth potential driven by advancements in genetic engineering for efficient pharmaceutical protein ...

TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the year Tessera to receive $150 ...

We've seen a US company bring the wolf species back from extinction after more than 10,000 years, and now the next animal on a "de-extinction" journey is New Zealand’s moa nunui (giant moa). The team ...